SII, the largest vaccine manufacturer in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it gets ready. The interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed that the vaccine was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants, AstraZeneca said in a statement.
